Skip to Content

Guggenheim Long Short Equity P RYSRX

Medalist Rating as of | See Guggenheim Investment Hub
  • NAV / 1-Day Return 22.81  /  +0.57 %
  • Total Assets 17.6 Mil
  • Adj. Expense Ratio
    1.760%
  • Expense Ratio 1.760%
  • Distribution Fee Level Above Average
  • Share Class Type No Load
  • Category Long-Short Equity
  • Investment Style Mid Value
  • Min. Initial Investment
  • Status Open
  • TTM Yield 0.21%
  • Turnover 329%

USD | NAV as of May 02, 2024 | 1-Day Return as of May 02, 2024, 10:27 PM GMT+0

Morningstar’s Analysis RYSRX

Will RYSRX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Weakness in Guggenheim Long Short Equity P's People and Process Pillar ratings limits this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYSRX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Ms Equity Custom Basket

5.55 857,923

Gs Equity Custom Basket

5.51 852,048

Microsoft Corp

1.81 279,774
Technology

Invesco Shrt-Trm Inv Trs Oblig Instl

1.64 252,908
Corporate

Qualcomm Inc

0.88 135,952
Technology

Merck & Co Inc

0.86 132,568
Healthcare

Johnson & Johnson

0.86 132,289
Healthcare

Toll Brothers Inc

0.85 132,085
Consumer Cyclical

Visa Inc Class A

0.85 131,997
Financial Services

Thermo Fisher Scientific Inc

0.85 131,636
Healthcare